Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.

ABSTRACT:

Rationale

Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but long-term side effects are unknown.

Objectives

To identify the types of exacerbations most likely to be reduced and clinical subgroups most likely to benefit from azithromycin, 250 mg daily, added to usual care.

Methods

Enrollment criteria included irreversible airflow limitation and AECOPD requiring corticosteroids, emergency department visit, or hospitalization in the prior year or use of supplemental oxygen. Recurrent events and cumulative incidence analyses compared treatment received for AECOPD by randomization group, stratified by subgroups of interest. Cox proportional hazards models estimated treatment effects in subgroups adjusted for age, sex, sm

SUBMITTER: Han MK 

PROVIDER: S-EPMC4226018 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature